Why the study?
Does Shenshao Ningxin Yin have a pharmacological role in treating COVID-19 with myocarditis?
Does Shenshao Ningxin Yin have a pharmacological role in treating COVID-19 with myocarditis?
Computational analysis suggests Shenshao Ningxin Yin has multi-target pharmacological potential for treating COVID-19 associated myocarditis.
Answers are grounded in this paper and cite their sources.
SNY should not yet inform clinical practice for COVID-19 myocarditis; leaves open validation of multi-target effects in human trials.
Our findings reveal the pharmacological role and molecular mechanism of SNY for the treatment of COVID-19 with myocarditis. We also, for the first time, demonstrate that SNY displays multi-component, multi-target, and multi-pathway characteristics with a complex mechanism of action.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: